Investor Presentation - Asia Dengue Summit
Open PDF
| Stock | Island Pharmaceuticals Ltd (ILA.ASX) |
|---|---|
| Release Time | 16 Jun 2026, 9:58 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Island Pharmaceuticals Presents Dengue Study Results at Asia Dengue Summit
Key Points
- CEO Dr. David Foster presented data from PROTECT study at Asia Dengue Summit
- ISLA-101 showed positive results in dengue prevention and treatment
- Plans to advance to future clinical trials based on promising results
- Discussions with potential partners for additional phase 2 and 3 trials
Full Summary
Island Pharmaceuticals Ltd, an Australian antiviral drug development company, announced that Dr. David Foster, CEO and Managing Director, presented new analysis of data from the PROTECT study at the 9th Asia Dengue Summit in Singapore. The study demonstrated that ISLA-101, a repurposed drug for dengue fever, showed positive results in both prevention and treatment. The prophylactic cohort experienced a meaningful reduction in viremia and symptoms, while the treatment cohort showed signals of drug effect. The company plans to advance to future clinical trials based on these promising results and is in discussions with potential partners for additional phase 2 and 3 trials.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In